ClinicalTrials.gg

Program

ARN-75039

A development code. Also written as “ARN-75039 high”, “ARN-75039 low” and “ARN-75039 oral capsules”.

Its studies are mostly in Neglected Diseases, led by Arisan Therapeutics.

Furthest: phase 2, since Feb 2, 20263 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Arisan Therapeutics30 open or runningphase 2since Feb 2, 2026Jan 27, 2023none ahead

Also a collaborator on its studies: federal-medical-centre-owo.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 27, 2023First study: phase 1 study in Healthy Adult ParticipantsFirst studyNCT05735249 · 94 enrolled · United States
  2. Mar 13, 2025Phase 1 study in Healthy VolunteerNCT06911242 · 16 enrolled · United States
  3. Feb 2, 2026Phase 2 study in Lassa FeverPhase 2 reachedNCT07419373 · 135 enrolled · United States, Nigeria

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07419373Lassa Fever · United States, Nigeria2SuspendedJun 2027135
NCT06911242Healthy Volunteer · United States1CompletedApr 21, 202516
NCT05735249Healthy Adult Participants · United States1CompletedMar 28, 202594

How it is read

Names in the registry

  • “ARN-75039 high”, 1 entry
  • “ARN-75039 low”, 1 entry
  • “ARN-75039 oral capsules”, 1 entry
  • “ARN-75039”, 1 entry

Codes read as this program: ARN75039.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
ARN-75039 (Arisan Therapeutics): development program | ClinicalTrials.gg